BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16625170)

  • 1. Handle with care.
    Macilwain C
    Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives. CMS and Wall Street report...
    Med Health; 2003 Jan; 57(4):7-8. PubMed ID: 12602066
    [No Abstract]   [Full Text] [Related]  

  • 3. Going over the patent cliff.
    Schommer JC
    Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 5. A change in the market--investing in diagnostics.
    Batchelder K; Miller P
    Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
    [No Abstract]   [Full Text] [Related]  

  • 6. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 7. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 8. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 9. [What drug companies actually do].
    Tonby K
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
    [No Abstract]   [Full Text] [Related]  

  • 10. [Free trade agreements make the drugs more expensive].
    Jeppsson A
    Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
    [No Abstract]   [Full Text] [Related]  

  • 11. Pfizer slashes R&D.
    Cressey D
    Nature; 2011 Feb; 470(7333):154. PubMed ID: 21307908
    [No Abstract]   [Full Text] [Related]  

  • 12. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 13. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 14. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 15. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 16. Lilly goes off Prozac.
    Simons J
    Fortune; 2004 Jun; 149(13):179-80, 182, 184. PubMed ID: 15241951
    [No Abstract]   [Full Text] [Related]  

  • 17. Rx for investors.
    Stires D
    Fortune; 2004 May; 149(9):158-60, 162, 164 passim. PubMed ID: 15124332
    [No Abstract]   [Full Text] [Related]  

  • 18. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
    Sherrid P
    US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
    [No Abstract]   [Full Text] [Related]  

  • 20. [Patients, patents and profits].
    Roland PC
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):205. PubMed ID: 18202741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.